We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04100720
Recruitment Status : Not yet recruiting
First Posted : September 24, 2019
Last Update Posted : February 10, 2023
Cardiovalve Ltd.
Cardiovascular Research Foundation, New York
Information provided by (Responsible Party):
Boston Biomedical Associates

Brief Summary:
This study is to evaluate the safety and technical performance of the Cardiovalve Transfemoral System for tricuspid valve replacement. Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

Condition or disease Intervention/treatment Phase
Tricuspid Regurgitation Device: Cardiovalve Transfemoral Tricuspid Valve Not Applicable

Detailed Description:

The Cardiovalve Transfemoral System for tricuspid valve replacement

Data collected in the clinical study will include 30-day safety and performance of the device and delivery system, and long-term clinical outcomes over a follow-up of 5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Feasibility Study of the Cardiovalve System for Tricuspid Regurgitation
Estimated Study Start Date : February 2024
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2030

Arm Intervention/treatment
Experimental: Cardiovalve Transfemoral Tricuspid Valve
Replacement (Implant) delivered through a transfemoral access
Device: Cardiovalve Transfemoral Tricuspid Valve
The Cardiovalve Transfemoral Tricuspid Valve System is intended for use in patients with severe, symptomatic Tricuspid regurgitation

Primary Outcome Measures :
  1. 1. Primary Performance Endpoint - Technical Success of Cardiovalve Delivery and Function in each participant [ Time Frame: 30 Days ]
    Cardiovalve Technical Success defined as: I Successful access, delivery and retrieval of the delivery system; II Successful deployment of correct positioning of the first intended implant; III Freedom from emergency surgery or reintervention related to the device or access procedure without any procedural mortality, stroke, and device dysfunction at 30-day follow-up.

  2. Primary Performance Endpoint - Clinical Performance - Reduction in Tricuspid Regurgitation severity measured using Echocardiography and compared to baseline [ Time Frame: 30 Days ]

    Cardiovalve Clinical Performance will be evaluated as: I The reduction in degree of tricuspid regurgitation measured immediately after the procedure compared to baseline; II The reduction in degree of tricuspid regurgitation measured at the time of discharge or 7 days post procedure, whichever comes first, in comparison with baseline

    Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+.

    0 = absent

    1. = mild
    2. = moderate
    3. = moderate to severe
    4. = severe

  3. Primary Safety Endpoint (Patient Based) Participants Implanted without Major Device Related Adverse Events through thirty days [ Time Frame: 30 Days ]
    The ability of the Cardiovalve to be implanted without Major Device Related Adverse Events through thirty (30) days including: I Death (Cardiovascular mortality vs non-cardiovascular); II Reintervention (operative or transcatheter) due to progressive or recurrent TR or device related complications; III Disabling stroke; IV Myocardial infarction (MVARC definition); V Major access site and vascular complications; VI Fatal or life-threatening bleeding (MVARC Type III-V); VII Arrhythmia and conduction disorder requiring permanent pacing; VIII Right coronary artery occlusion requiring intervention; IX Cardiac tamponade, X Renal failure requiring dialysis

Secondary Outcome Measures :
  1. Secondary Performance Endpoint - Tricuspid Regurgitation Severity [ Time Frame: 30 days, 3 months, 6 months ]

    Tricuspid Regurgitation is measured using Echocardiography and is graded based on degree of severity using grading conventions from 0 to 4+.

    0 = absent

    1. = mild
    2. = moderate
    3. = moderate to severe
    4. = severe

  2. Secondary Performance Endpoint - Cusp Insufficiency [ Time Frame: 30 days, 3 months, 6 months ]
    Cusp Insufficiency: Change in the degree of the cusp insufficiency as assessed with echocardiography (ordinal) from a higher to a lower value

  3. Secondary Performance Endpoint - Unrestricted Movement of Cusps [ Time Frame: 30 days, 3 months, 6 months ]
    Unrestricted Movement of Cusps: the percentage of medical devices with unrestricted movement of cusps after implantation as assessed with echocardiography

  4. Secondary Performance Endpoint - New York Heart Association (NYHA) functional class [ Time Frame: 30 days, 3 months, 6 months ]

    NYHA function class I - IV; Higher functional class represents more severe symptoms of heart failure

    NYHA Classification - The Stages of Heart Failure:

    1. Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc.
    2. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.
    3. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m).Comfortable only at rest.
    4. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients.

  5. Secondary Performance Endpoint - 6 minute walk test [ Time Frame: 30 days, 3 months, 6 months ]
    6 minute walk test distance (meters)

  6. Secondary Performance Endpoint - Kansas City Cardiomyopathy Questionnaire [ Time Frame: 30 days, 3 months, 6 months ]

    Kansas City Cardiomyopathy Questionnaire (KCCQ) - 23 subjective quality of life questions. Assessed before and after implantation. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    There are 3 subscales: Symptom Burden - range 0-100; Physical Limitation - range 0-100; Quality of Life - range 0-100; The total KCCQ score represents the mean (average) of the three subscale scores.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 84 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participant is 85 ≥ Age ≥ 18 years
  2. Participant has severe, symptomatic tricuspid regurgitation (TR) ≥ 3+ based upon echocardiography, as assessed by Independent core laboratory
  3. Participant is New York Heart Association (NYHA) Class II-IVa
  4. Participant has left ventricular ejection fraction (LVEF) ≥ 35%
  5. Participant distance of 6 minute walk test (6MWT) ≥ 60 m
  6. Participant adequately treated based upon medical standards, including for coronary artery disease, mitral regurgitation and Guideline Directed Medical Therapy (GDMT) for heart failure for at least 30-days prior to index procedure.
  7. Acceptable by the site "Heart Team" including an interventional cardiologist, cardiothoracic surgeon, heart failure cardiologist and recommended as a candidate for the Cardiovalve System
  8. Participant approved by the Subject Screening Committee

Exclusion Criteria:

  1. Known significant intracardiac shunt (e.g. septal defect) or congenital structural heart disease (PFO's without significant shunts are allowed)
  2. Significant coronary artery disease requiring treatment
  3. Primary tricuspid disease (e.g. rheumatic, myxomatous degeneration, tricuspid valve prolapse)
  4. Severe right ventricular failure per ASE guidelines1
  5. Systolic pulmonary arterial pressure > 65 mmHg as assessed by transthoracic echocardiography
  6. Presence of any known life threatening non-cardiac disease that will limit the subject's life expectancy to less than one year
  7. Cerebrovascular event (stroke, TIA) within the past 3 months
  8. Active endocarditis or history of mitral/tricuspid endocarditis within the last 12 months
  9. Patient has significant left sided valvular heart disease which requires treatment (e.g. mitral regurgitation or stenosis, and aortic regurgitation or stenosis)
  10. Documented primary coagulopathy or platelet disorder, including thrombocytopenia (absolute platelet count <90k)
  11. Documented evidence of significant renal dysfunction (eGFR<30 ml/min/1.73m2) or on any form of dialysis at time of screening within the last 4 weeks
  12. Contraindication or known allergy to device's components, to anti-coagulation therapy with vitamin K antagonists or to contrast media that cannot be adequately premedicated
  13. Patients unsuitable for implantation because of thrombosis of the lower venous system or presence of a vena cava filter
  14. The patient has contraindication against a transesophageal echo (TEE) during the procedure
  15. Evidence of an acute myocardial infarction (AMI) ≤ 1 month (30 days)
  16. Hepatic insufficiency (MELD > 10)
  17. Female patient of child-bearing potential
  18. Psychiatric or behavioral disease including known alcohol or drug abuser that is likely to impair compliance with protocol
  19. Requirement for Antibiotic Treatment within the last 48 hours
  20. Cardiac Anatomy deemed not suitable for the Cardiovalve Implant
  21. Surgical or interventional procedure planned within 30 days prior to index procedure
  22. UNOS Status 1 heart transplant or prior orthotropic heart transplantation.
  23. Any prior Tricuspid valve surgery or transcatheter Tricuspid valve procedure
  24. Modified Rankin Scale > 4 disability
  25. Implant or revision of any rhythm management device (CRT or CRT-D) or implantable cardioverter-defibrillator within one month prior to index procedure
  26. Need for any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days of index procedure
  27. Currently participating in an investigational drug or another device study which has not reached its primary endpoint
  28. Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment
  29. Chronic oral steroid or other condition that could impair healing response (e.g. cardiac sarcoidosis or other chronic inflammatory disease).
  30. Acutely decompensated heart failure (i.e. hemodynamically unstable or requiring IV inotrope ) at the time of screening
  31. Severe COPD or continuous use of home oxygen
  32. Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study
  33. Aortic or pulmonic valve disease requiring surgery
  34. Venous peripheral anatomy unsuitable for implant delivery
  35. Chronic anemia (Hgb < 9)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04100720

Layout table for location contacts
Contact: Lauren Baker, PhD (508) 351-8632 lbaker@boston-biomedical.com
Contact: Karen Pierce, MS (508) 351-8632 kpierce@boston-biomedical.com

Layout table for location information
United States, Illinois
Northwestern University / Bluhm Cardiovascular Institute
Chicago, Illinois, United States, 60611
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10461
Principal Investigator: Azeem Latib, MD         
Columbia University Medical Center / NYPH
New York, New York, United States, 10032
Principal Investigator: Tamim Nazif, MD         
Sponsors and Collaborators
Boston Biomedical Associates
Cardiovalve Ltd.
Cardiovascular Research Foundation, New York
Layout table for additonal information
Responsible Party: Boston Biomedical Associates
ClinicalTrials.gov Identifier: NCT04100720    
Other Study ID Numbers: CP 19-01
First Posted: September 24, 2019    Key Record Dates
Last Update Posted: February 10, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Tricuspid Valve Insufficiency
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases